tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RIGL Stock Latest News

Rigel Pharmaceuticals Reports Record Q3 Revenue and Growth
Company AnnouncementsRigel Pharmaceuticals Reports Record Q3 Revenue and Growth
8d ago
RIGL
Rigel Pharmaceuticals upgraded to Buy at Jefferies on strong execution
PremiumThe Fly
Rigel Pharmaceuticals upgraded to Buy at Jefferies on strong execution
8d ago
RIGL
Rigel Pharmaceuticals upgraded to Buy from Hold at Jefferies
PremiumThe Fly
Rigel Pharmaceuticals upgraded to Buy from Hold at Jefferies
8d ago
RIGL
Midday Fly By: Broader market bought on dip after tech selloff
PremiumThe Fly
Midday Fly By: Broader market bought on dip after tech selloff
8d ago
BW
KW
Rigel Pharmaceuticals price target raised to $38 from $32 at Cantor Fitzgerald
PremiumThe Fly
Rigel Pharmaceuticals price target raised to $38 from $32 at Cantor Fitzgerald
8d ago
RIGL
Rigel Pharmaceuticals Reports Strong Q3 2025 Results
PremiumCompany AnnouncementsRigel Pharmaceuticals Reports Strong Q3 2025 Results
9d ago
RIGL
Rigel Pharmaceuticals reports Q3 EPS $1.46, consensus 94c
Premium
The Fly
Rigel Pharmaceuticals reports Q3 EPS $1.46, consensus 94c
9d ago
RIGL
Rigel Pharmaceuticals raises FY25 revenue view to $285M-$290M from $270M-$280M
Premium
The Fly
Rigel Pharmaceuticals raises FY25 revenue view to $285M-$290M from $270M-$280M
9d ago
RIGL
Is RIGL a Buy, Before Earnings?
PremiumPre-Earnings
Is RIGL a Buy, Before Earnings?
11d ago
RIGL
Rigel’s Strategic Advancements and Financial Projections Justify Buy Rating
PremiumRatings
Rigel’s Strategic Advancements and Financial Projections Justify Buy Rating
1M ago
RIGL
Rigel Pharmaceuticals: First patient enrolled in Phase 1b study of R289
PremiumThe Fly
Rigel Pharmaceuticals: First patient enrolled in Phase 1b study of R289
1M ago
RIGL
Eli Lilly and Rigel’s Promising Study on Rheumatoid Arthritis Treatment
PremiumCompany Announcements
Eli Lilly and Rigel’s Promising Study on Rheumatoid Arthritis Treatment
3M ago
LLY
RIGL
Rigel Pharmaceuticals’ Earnings Call Highlights Robust Growth
PremiumCompany AnnouncementsRigel Pharmaceuticals’ Earnings Call Highlights Robust Growth
3M ago
RIGL
Rigel’s Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
Premium
Ratings
Rigel’s Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
3M ago
RIGL
Rigel Pharmaceuticals Reports Strong Q2 2025 Results
Premium
Company Announcements
Rigel Pharmaceuticals Reports Strong Q2 2025 Results
3M ago
RIGL
Rigel Pharmaceuticals raises FY25 revenue view to $270M-$280M from $200M-$210M
PremiumThe Fly
Rigel Pharmaceuticals raises FY25 revenue view to $270M-$280M from $200M-$210M
3M ago
RIGL
Rigel Pharmaceuticals reports Q2 EPS $3.91, consensus $1.40
PremiumThe Fly
Rigel Pharmaceuticals reports Q2 EPS $3.91, consensus $1.40
3M ago
RIGL
Rigel Pharmaceuticals (RIGL) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Rigel Pharmaceuticals (RIGL) Q2 Earnings Cheat Sheet
3M ago
RIGL
Eli Lilly and Rigel Pharmaceuticals: Promising Advances in Rheumatoid Arthritis Treatment
PremiumCompany Announcements
Eli Lilly and Rigel Pharmaceuticals: Promising Advances in Rheumatoid Arthritis Treatment
4M ago
LLY
RIGL
Eli Lilly and Rigel Pharmaceuticals Advance Rheumatoid Arthritis Study with LY3871801
PremiumCompany AnnouncementsEli Lilly and Rigel Pharmaceuticals Advance Rheumatoid Arthritis Study with LY3871801
4M ago
LLY
RIGL
Promising Efficacy and Market Potential for GAVRETO in RET Fusion-Positive Tumors
Premium
Ratings
Promising Efficacy and Market Potential for GAVRETO in RET Fusion-Positive Tumors
5M ago
RIGL
Rigel Pharmaceuticals Approves Equity Plan Amendment
Premium
Company Announcements
Rigel Pharmaceuticals Approves Equity Plan Amendment
6M ago
8K
RIGL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >